Using a unique processing technology, Osteotech helped create a market for allograft tissue transplants by increasing availability and improving quality. Riding that technology, Osteotech has gone from providing services to developing products with a line of proprietary allograft tissue, expanding a market in which it remains the leader. While the tissue market is growing and attracting competition from large orthopedic companies, surgeons have been slow in coming around, concerned largely by safety issues similar to those facing blood products. And the specter of a biological solution hovers over the tissue transplant field. Yet, Osteotech remains confident it can continue to grow and fend off major competitors, while expanding internationally and adding spinal implants to the company's tissue products.
by Stephen Levin
The orthopedic device industry traditionally has been one of metal and plastic, where hardware is king and innovation means a...
Join thousands of industry professionals who rely on In Vivo for daily insights
Already a subscriber?
Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.
The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.
In the latest podcast interview, Phil L'Huillier, CEO of Scancell, discussed the company's work in cancer vaccine development, and its selection as the first British biotech to be a part of the NHS Cancer Vaccine Launch Pad.
New report by global law firm Taylor Wessing and Bayes Business School forecasts a steadily increasing volume of major life sciences M&A in the coming five years, but highlights concerns over cybersecurity and unrealistic valuations. Taylor Wessing partner Andrew Edge spoke to In Vivo.
The Chinese appetite for GLP-1s is noticeable. While the market opportunity for western pharma is huge, so are the strategic market access challenges, though not unsurmountable, L.E.K. Consulting told In Vivo.
